Scarica l'app Stockscreener
0.00
0.00%
0.00
Precedente Chiudi:
$0.00
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
Capitalizzazione di mercato:
$N/A
Reddito:
$1.65M
Utile/perdita netta:
$-5.91M
Rapporto P/E:
0.00
EPS:
-0.1707
Flusso di cassa netto:
$-3.03M
1 W Prestazione:
+0.00%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$0.00
Vitro Biopharma, Inc. Stock (VTRO) Company Profile
Nome
Vitro Biopharma, Inc.
Settore
Industria
Telefono
(720) 859-4120
Indirizzo
4621 TECHNOLOGY DRIVE, GOLDEN
Compare VTRO vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRO
Vitro Biopharma, Inc.
|
0.00 | 0 | 1.65M | -5.91M | -3.03M | -0.1707 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Vitro Biopharma, Inc. Borsa (VTRO) Ultime notizie
VTRO (Vitro Biopharma) PB Ratio : 0.00 (As of Mar. 26, 2026) - GuruFocus
Cue Biopharma to present new in vitro data for CUE-401 - TipRanks
Cue Biopharma unveils in vitro data for CUE-401 in autoimmune disease research - Traders Union
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - The Manila Times
CUE-401 lab data hint at rebalancing immune attacks in autoimmune disease - Stock Titan
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2025 - marketscreener.com
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Reviewing Rein Therapeutics (NASDAQ:RNTX) and Vitro Diagnostics (OTCMKTS:VODG) - Defense World
Financial Contrast: Imunon (NASDAQ:IMNN) vs. Vitro Diagnostics (OTCMKTS:VODG) - Defense World
What Stem Cell Clinics Do You Trust? - BioInformant
10 cultured meat companies driving sustainable food in 2025 - Labiotech.eu
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells(R) to Treat COVID-19 - ACCESS Newswire
The 16th international oncolytic virotherapy conference: from in vitro to clinical studies, novel approaches in cancer therapy meeting report - Frontiers
Dealmaking Quarterly Statistics, Q4 2024 - Citeline News & Insights
Stem Cell Therapy for the Coronavirus COVID-19 Pandemic - ACCESS Newswire
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner - Business Wire
Closing the women’s health gap: Biopharma’s untapped opportunity - McKinsey & Company
Layoffs Continued Across Biopharma in 2024 - BioSpace
In Vitro Diagnostics (IVD) Market Size to Surpass USD 157.56 Billion by 2034 - BioSpace
Swiss biotech going strong in 2024: 18 companies to put on your radar - Labiotech.eu
Vitro Biopharma | CORRESP: CORRESP - Moomoo
Top 5 In-Vitro Diagnostics [IVD] Companies - Fortune Business Insights
A biotech working on a new approach to IVF raises $33M in fresh funding - BioPharma Dive
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications - BioSpace
FDA defends lab test rule, as critics fear industry upheaval - BioPharma Dive
ProteoMixture: A cell type deconvolution tool for bulk tissue proteomic data - ScienceDirect.com
EDGAR Filing Documents for 0001493152-24-004779 - SEC.gov
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
SIRION Biotech - Pharmaceutical Technology
Vitro Biopharma, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Kirk Cousins travels to Caribbean for stem cell treatment - kare11.com
Tickers - Finansavisen
In Vitro Fertilization (IVF) Market Size & Share to Surpass $1296.47 Mn by 2030 | Vantage Market Research - Yahoo Finance
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
Vitro Biopharma, Inc. announced a financing transaction - marketscreener.com
Global Stem Cells Market Research Report 2023: Implications - GlobeNewswire
Vitro Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
The Next Normal – The future of biotech: AI-driven drug discovery - McKinsey & Company
FUJIFILM Irvine Scientific PRIME-XV Stem FreezIS DMSO-Free Cryopreservation Medium to be Used in FDA-Authorized Clinical Trial - Business Wire
GT Biopharma Poster Presentation and Mini Oral Session at - GlobeNewswire
Vitro Biopharma Names Chris Furman Chief Executive Officer - Yahoo Finance
Biotech - McKinsey & Company
Business of Biotechniques 2022 - BioTechniques
Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine - Stock Titan
Developing A Robust In Vitro Intestinal Model For Preclinical Candidate Screening Of GI Toxicity - pharmaceuticalonline.com
FinancialContentAytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells - FinancialContent
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19 - BioInformant
DVC Stem: Stem Cell Therapy Clinic in the Cayman Islands - BioInformant
In vitro glycoengineeringSuitability for BioPharma manufacturing - Labroots
Critically Ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R) - BioInformant
Vitro Biopharma, Inc. Azioni (VTRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Capitalizzazione:
|
Volume (24 ore):